Table 1.
Baseline characteristics of patients treated with venetoclax and decitabine or azacitidine. There were no statistical differences between groups in any of the subcategories
| Baseline Characteristics | |||
|---|---|---|---|
| Characteristic | All patients (N = 57) |
Decitabine-venetoclax (N = 35) |
Azacitidine-venetoclax (N = 22) |
| Male sex – no. (%) | 28 (49.1) | 17 (48.6) | 11 (50.0) |
| Age at diagnosis – yr. | |||
| Median | 60 | 62 | 59 |
| Range | 23 – 81 | 23 – 81 | 23 – 76 |
| Race – no. (%)A | |||
| Black | 12 (21.4) | 10 (29.4) | 2 (9.1) |
| White | 43 (76.8) | 23 (67.6) | 20 (90.9) |
| Other | 1 (1.8) | 1 (2.9) | 0 (0) |
| ELN 2022 cytogenetic risk group – no. (%) | |||
| Favorable | 8 (14.0) | 7 (20.0) | 1 (4.5) |
| Intermediate | 12 (21.1) | 6 (17.1) | 6 (2.3) |
| Adverse | 37 (64.9) | 22 (62.9) | 15 (68.2) |
| Molecular aberrations – no. (%)B | |||
| ASXL1 | 10 (18.2) | 6 (17.6) | 4 (19.0) |
| BCOR | 3 (5.5) | 2 (5.9) | 1 (4.8) |
| BCR::ABL1 | 1 (1.8) | 1 (2.9) | 0 (0) |
| CEBPA biallelic | 1 (1.8) | 1 (2.9) | 0 (0) |
| CEBPA monoallelic | 2 (3.6) | 1 (3.7) | 1 (4.8) |
| DNMT3A | 11 (20.0) | 4 (11.8) | 7 (33.3) |
| FLT3-ITD | 11 (20.0) | 6 (17.6) | 5 (23.8) |
| FLT3-TKD | 9 (16.4) | 7 (20.6) | 2 (9.5) |
| IDH1 | 5 (9.1) | 4 (11.8) | 1 (4.8) |
| IDH2 | 6 (10.9) | 2 (5.9) | 4 (19.0) |
| KRAS | 6 (10.9) | 5 (14.7) | 1 (4.8) |
| NPM1 | 13 (23.6) | 9 (26.5) | 4 (19.0) |
| NRAS | 12 (21.8) | 7 (20.6) | 5 (23.8) |
| RUNX1 | 9 (16.4) | 7 (20.6) | 2 (9.5) |
| SF3B1 | 1 (1.8) | 1 (2.9) | 0 (0) |
| SRSF2 | 5 (9.1) | 3 (8.8) | 2 (9.5) |
| STAG2 | 7 (12.7) | 4 (11.8) | 3 (14.3) |
| TP53 | 9 (16.4) | 7 (20.6) | 2 (9.5) |
| U2AF1 | 3 (5.5) | 1 (2.9) | 2 (9.5) |
| ZRSR2 | 4 (7.3) | 2 (5.9) | 2 (9.5) |
| AML-MRC – no. (%)C | 12 (22.6) | 8 (25.0) | 4 (19.0) |
| Previously diagnosed MDS – no. (%) | 4 (7.0) | 3 (8.6) | 1 (4.5) |
| Charlson comorbidity index score | |||
| Median | 4 | 5 | 4 |
| Range | 2 – 14 | 2 – 14 | 2 – 7 |
| ECOG at diagnosis | |||
| Median | 1 | 1 | 1 |
| Range | 0 – 3 | 0 – 3 | 0 – 3 |
| Prior stem cell transplant – no. (%) | 8 (14.0) | 3 (8.6) | 5 (19.0) |
| Prior hypomethylating agent – no. (%) | 11 (19.3) | 6 (17.1) | 5 (22.7) |
| Disease status – no. (%) | |||
| Relapsed | 24 (42.1) | 13 (37.1) | 11 (50.0) |
| Refractory | 33 (57.9) | 22 (62.9) | 11 (50.0) |
| Prior lines of therapy | |||
| Median | 1 | 1 | 1 |
| Range | 1 – 7 | 1 – 4 | 1 – 7 |
| Number of cycles | |||
| Median | 2 | 2 | 3 |
| Range | 1 – 10 | 1 – 10 | 1 – 9 |
A:
Race was known in 56 of 57 patients
B:
Fifty-five of 57 patients had NGS evaluable prior to initiation of venetoclax
C:
Fifty-three of 57 patients were evaluable for AML-MRC at the time of diagnosis